JP2023527153A5 - - Google Patents
Info
- Publication number
- JP2023527153A5 JP2023527153A5 JP2022570474A JP2022570474A JP2023527153A5 JP 2023527153 A5 JP2023527153 A5 JP 2023527153A5 JP 2022570474 A JP2022570474 A JP 2022570474A JP 2022570474 A JP2022570474 A JP 2022570474A JP 2023527153 A5 JP2023527153 A5 JP 2023527153A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- composition according
- salt
- 25hc3s
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029361P | 2020-05-22 | 2020-05-22 | |
| US63/029,361 | 2020-05-22 | ||
| US202063030207P | 2020-05-26 | 2020-05-26 | |
| US63/030,207 | 2020-05-26 | ||
| US202063113116P | 2020-11-12 | 2020-11-12 | |
| US63/113,116 | 2020-11-12 | ||
| US202163146555P | 2021-02-05 | 2021-02-05 | |
| US63/146,555 | 2021-02-05 | ||
| PCT/US2021/033743 WO2021237143A1 (en) | 2020-05-22 | 2021-05-21 | Treatment of non-alcoholic steatohepatitis (nash) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527153A JP2023527153A (ja) | 2023-06-27 |
| JP2023527153A5 true JP2023527153A5 (enExample) | 2024-05-28 |
Family
ID=78707644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570474A Pending JP2023527153A (ja) | 2020-05-22 | 2021-05-21 | 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230181601A1 (enExample) |
| EP (1) | EP4153164A4 (enExample) |
| JP (1) | JP2023527153A (enExample) |
| KR (1) | KR20230015939A (enExample) |
| CN (1) | CN115916181A (enExample) |
| AU (1) | AU2021273936A1 (enExample) |
| BR (1) | BR112022022737A2 (enExample) |
| CA (1) | CA3195103A1 (enExample) |
| MX (1) | MX2022014575A (enExample) |
| TW (1) | TW202210081A (enExample) |
| WO (1) | WO2021237143A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3494125B1 (en) | 2016-08-02 | 2022-06-22 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| WO2006047022A1 (en) * | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| US8399441B2 (en) * | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
| US9034859B2 (en) * | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| MX360979B (es) * | 2011-09-16 | 2018-11-22 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico. |
| US9889108B2 (en) * | 2013-03-15 | 2018-02-13 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| EP3494125B1 (en) * | 2016-08-02 | 2022-06-22 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| EP3493810A4 (en) * | 2016-08-02 | 2020-04-08 | Durect Corporation | COMPOSITIONS WITH OXYGENOUS CHOLESTERINSULFATE AND AT LEAST POLYALKYLENE GLYCOL, CARBOXYMETHYLCELLULOSE OR POLYOXYL GLYCERIDE |
| JP7266531B2 (ja) * | 2017-04-18 | 2023-04-28 | ジェンフィ | エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ |
| US10980810B2 (en) * | 2017-10-06 | 2021-04-20 | Gilead Sciences, Inc. | Combination therapy comprising an ACC inhibitor |
-
2021
- 2021-05-21 BR BR112022022737A patent/BR112022022737A2/pt not_active Application Discontinuation
- 2021-05-21 AU AU2021273936A patent/AU2021273936A1/en active Pending
- 2021-05-21 JP JP2022570474A patent/JP2023527153A/ja active Pending
- 2021-05-21 EP EP21808175.0A patent/EP4153164A4/en active Pending
- 2021-05-21 CA CA3195103A patent/CA3195103A1/en active Pending
- 2021-05-21 TW TW110118457A patent/TW202210081A/zh unknown
- 2021-05-21 WO PCT/US2021/033743 patent/WO2021237143A1/en not_active Ceased
- 2021-05-21 MX MX2022014575A patent/MX2022014575A/es unknown
- 2021-05-21 US US17/924,101 patent/US20230181601A1/en active Pending
- 2021-05-21 CN CN202180049351.XA patent/CN115916181A/zh active Pending
- 2021-05-21 KR KR1020227043976A patent/KR20230015939A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101465715B1 (ko) | 심혈관 이벤트 발병 예방용 조성물 | |
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| JP2022177142A5 (enExample) | ||
| RU2008144136A (ru) | Твердая пероральная лекарственная форма, содержащая усилитель | |
| JP2012176987A (ja) | 脂質療法用のオメガ−３脂肪酸類及び異常脂質血症薬剤 | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| JP2024507810A5 (enExample) | ||
| JP2018508551A5 (ja) | 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物 | |
| JP2023538522A5 (enExample) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| IL274414B1 (en) | Oral rifamycin sv compositions | |
| JP2023526418A5 (enExample) | ||
| IL310115A (en) | Treatment of his hyporesponders | |
| JP2023527153A5 (enExample) | ||
| WO2013073884A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| CN100502870C (zh) | 含有瑞舒伐他汀或匹伐他汀和b族维生素的药物组合物 | |
| US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
| WO2020028124A1 (en) | NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS | |
| CA2480275A1 (en) | Statin therapy for enhancing cognitive maintenance | |
| JP2005525391A5 (enExample) | ||
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| KR101830977B1 (ko) | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 | |
| CN102416015B (zh) | 一种含他汀类药物的组合物及其用途 | |
| Brinton | Newer HMG‐CoA reductase inhibitor (statin) therapies | |
| TW200404533A (en) | Blood lipid ameliorant compositions |